Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: Approximately 10-15 % of endometrial cancer patients with tumors confined to the uterus (FIGO 2009 stage I) demonstrate recurrence and the oncologic outcomes are highly related to recurrence patterns. This study aimed to verify whether the FIGO 2023 staging system could discriminate outcomes.
Materials And Methods: Between January 2010 and March 2019, 536 FIGO 2009 stage I patients were eligible for this retrospective cohort study. Patient characteristics and clinicopathological data were retrieved from electronic medical records. The patients were reclassified according to the FIGO 2023 staging criteria. Oncological outcomes included the recurrence rate, recurrence pattern, and overall survival.
Results: Among the 536 eligible patients, the (sub)stage migration rate was 23.5 % from the FIGO 2009 to the FIGO 2023 stage system. FIGO 2023 staging system resulted in (sub)stage up-migration, mostly owing to aggressive histological types. A higher recurrence rate was detected in the FIGO 2023 stage II patients (12.3 %) compared to the stage I patients (6.9 %). In comparison to the FIGO 2023 stage I patients, the stage II patients had a higher distant recurrence rate (8.8 % vs. 2.6 %) and poorer overall survival (38.0 vs 69.0 months, p = 0.02).
Conclusion: Patients who are upstaged are prone to worse oncological outcomes, including distant recurrence and mortality. Therefore, comprehensive adjuvant treatment strategies based on each FIGO 2023 substage are imperative.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.tjog.2024.09.020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Gene actionability according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) in No Specific Molecular Profile (NSMP) endometrial cancer.
ESMO Open
September 2025
Unit of Oncological Gynecology, Women's Children's and Public Health Department, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy; Università Cattolica del Sacro Cuore, Rome, Italy. Electronic address: https://twitter.com/camillanero.
Background: The No Specific Molecular Profile (NSMP) subtype accounts for ∼30%-40% of endometrial cancer (EC), comprising a heterogeneous group of EC.
Patients And Methods: The primary outcome of this study was the prevalence of actionable genomic alterations in NSMP EC, classified according to the European Society for Medical Oncology (ESMO) Scale for Clinical Actionability of molecular Targets (ESCAT). Oncogenic and likely oncogenic alterations, pathways, and co-mutation patterns were reported.
Young Women With Endometrial Cancer: A Portuguese Perspective.
Cancer Diagn Progn
September 2025
Gynecology Department, Instituto Português de Oncologia Francisco Gentil de Lisboa, Lisbon, Portugal.
Background/aim: Endometrial cancer (EC) is rare in premenopausal women. The aim of this study was to describe the demographic, clinical and pathological characteristics and compare survival in the light of pathological aspects of EC in young women.
Patients And Methods: We performed a retrospective observational cohort study, analyzing data from 29 women up to 45 years of age diagnosed between 2003 and 2023 at our Institution.
Optimizing bevacizumab dosing in first-line ovarian cancer treatment: the PGOG-ov1 trial.
Trials
September 2025
Independent Laboratory of Translational Medicine, Chair of Medical Genetics, Medical University of Lublin, Lublin, Poland.
The management of advanced ovarian cancer has significantly developed with the integration of bevacizumab into standard therapeutic regimens. While the efficacy of bevacizumab has been established in trials such as GOG218, ICON7, and PAOLA-1, there remains a gap in understanding the advantages of the 7.5 mg/kg dose over the 15 mg/kg regimen.
View Article and Find Full Text PDFDoes BRCA Mutation Status Influence Ovarian Cancer Onset Timing and Patients' Treatment Outcomes?
Genes (Basel)
July 2025
Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Powstancow Wielkopolskich 72, 70-111 Szczecin, Poland.
Background/objectives: Mutations in the and genes are well-known risk factors for ovarian cancer. They are also associated with response to platinum-based chemotherapy; however, their definitive impact on patient prognosis remains not fully understood. This study aimed to investigate the influence of mutation status on the age of ovarian cancer onset and on treatment outcomes in patients with high-grade serous ovarian cancer.
View Article and Find Full Text PDFSurvival rates of cervical cancer patients in Sarawak: a single-centre referral study.
BMC Cancer
August 2025
School of Health and Medical Sciences, Institute of Infection and Immunity, City St George's University of London, London, UK.
Background: Cervical cancer represents a significant health challenge in Malaysia, especially in the state of Sarawak which records some of the highest incidence rates across the country. This study evaluates the survival rates of cervical cancer patients in Sarawak, focusing on demographic characteristics, disease stage and survival outcomes to inform healthcare strategies.
Methods: A retrospective case notes review of disease stage, patterns of care and survival outcomes of patients diagnosed with cervical cancer at Sarawak General Hospital between January 2018 to December 2022 was conducted.